共 50 条
- [1] Real-world dosing patterns of everolimus-based lines of therapy among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor-negative (HR+/HER2-) metastatic breast cancer (mBC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Princic, NicoleBrouillette, MatthewTang, DerekLin, ChinjuneLanoue, BradBarghout, Victoria E.
- [2] PALBOCICLIB DOSING, WASTAGE AND COSTS AMONG POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR/HER2-) METASTATIC BREAST CANCER (MBC): A CLAIMS ANALYSISVALUE IN HEALTH, 2017, 20 (05) : A105 - A105Princic, N.Brouillette, M.Tang, D.Lanoue, B.Barghout, V
- [3] PIK3CA mutation testing prevalence among post-menopausal (PM) women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) using real world dataCANCER RESEARCH, 2020, 80 (04)Princic, NicoleSaid, QayyimSmith, DavidJohnson, WilliamAizer, Ayal
- [4] Healthcare medical costs among post-menopausal women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) managed with systemic therapy following CDK 4/6 inhibitor (CDKi) in the real-world setting.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Princic, NicoleTang, DerekBardia, AdityaSmith, DavidJohnson, William M.Aizer, Ayal
- [5] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast CancerPATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062Engel-Nitz, Nicole M.Johnson, Mary G.Johnson, Michael P.Cha-Silva, Ashley S.Kurosky, Samantha K.Liu, Xianchen
- [6] "Real world" characteristics, treatment patterns and outcomes of patients with hormone receptor positive (HR plus ), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC)CANCER RESEARCH, 2019, 79 (04)Twelves, C.Cheeseman, S.Thompson, M.Riaz, M.Perren, T.Ahat-Donker, N.Sopwith, W.Myland, M.Lee, A.Turner, S.Hall, G.
- [7] Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancerCURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (08) : 1573 - 1582Li, NanxinHao, YanniXie, JipanLin, Peggy L.Zhou, ZhouZhong, YichenSignorovitch, James E.Wu, Eric Q.
- [8] Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2- metastatic breast cancerJOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 315 - 326Hao, YanniLin, Peggy L.Xie, JipanLi, NanxinKoo, ValerieOhashi, ErikaWu, Eric Q.Rogerio, Jaqueline
- [9] Real-world treatment durations without chemotherapy (CT) for hormone-receptor-positive (HR plus )/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC)CANCER RESEARCH, 2015, 75Swallow, ElyseWang, JennyThomason, DarrenTan, Ruo-DingKageleiry, AndrewSignorovitch, James
- [10] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARKVALUE IN HEALTH, 2019, 22 : S483 - S483Moller, A. H.Oddershede, L.